Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $59 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Brandon Folkes has reiterated an Overweight rating on Sanara MedTech (NASDAQ:SMTI) and maintained a $59 price target.
August 22, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Sanara MedTech and maintained a $59 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Sanara MedTech. The maintained price target of $59 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100